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Transforming growth-factor-beta1Transforming growth factor-beta (TGF-β1) is implicated in the onset and progression of renal ﬁbrosis and di-
abetic nephropathy (DN), leading to a loss of epithelial characteristics of tubular cells. The transcriptional
proﬁle of renal tubular epithelial cells stimulated with TGF-β1 was assessed using RNA-Seq, with 2027 differ-
entially expressed genes identiﬁed. Promoter analysis of transcription factor binding sites in the TGF-β1 re-
sponsive gene set predicted activation of multiple transcriptional networks, including NFκB. Comparison of
RNA-Seq with microarray data from identical experimental conditions identiﬁed low abundance transcripts
exclusive to RNA-Seq data. We compared these ﬁndings to human disease by analyzing transcriptomic
data from renal biopsies of patients with DN versus control groups, identifying a shared subset of 179 regu-
lated genes. ARK5, encoding an AMP-related kinase, and TGFBI — encoding transforming growth factor, beta-
induced protein were induced by TGF-β1 and also upregulated in human DN. Suppression of ARK5 attenuat-
ed ﬁbrotic responses of renal epithelia to TGF-β1 exposure; and silencing of TGFBI induced expression of the
epithelial cell marker — E-cadherin. We identiﬁed low abundance transcripts in sequence data and validated
expression levels of several transcripts (ANKRD56, ENTPD8) in tubular enriched kidney biopsies of DN pa-
tients versus living donors. In conclusion, we have deﬁned a TGF-β1-driven pro-ﬁbrotic signal in renal epi-
thelial cells that is also evident in the DN renal transcriptome.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Diabetic nephropathy (DN) is the leading cause of end stage renal
disease worldwide, affecting approximately 25–30% of those with di-
abetes [1]. With the escalating prevalence of diabetes there is a signif-
icant rise in the incidence of DN and other diabetic microvascular
complications. DN reﬂects the convergence of metabolic and hemo-
dynamic insults, renal podocyte loss, albuminuria, mesangial cellsigned the research; E.P.B. and
analyzed data; and F.M., C.G.,
r. Data deposition: Transcrip-
in the Gene Expression Omni-
rray: accession no. GSE23338;
s work.
tary Details.
rights reserved.hypertrophy, glomerulosclerosis and tubulointerstitial ﬁbrosis (TIF)
[2]. There is an urgent need to better understand the molecular
basis underlying the initiation and progression of DN with a view to
deﬁning new biomarkers and targets for therapeutic intervention.
TIF is proposed to develop through proliferation and activation of res-
ident ﬁbroblasts, recruitment of circulating ﬁbrocytes and by trans-
formation of epithelial and other resident cells to a mesenchymal
phenotype (EMT — epithelial–mesenchymal transformation) [3].
Transforming growth factor-β1 (TGF-β1) is implicated in the de-
velopment of diabetic glomerulosclerosis and there is a more recent
appreciation of its role as a key driver of TIF [2,4]. TGF-β1 is a member
of the TGF-β superfamily of proteins, consisting of three ligands (TGF-
β1, 2 and 3) together with the activins/inhibins and the bone mor-
phogenic proteins. This family is involved in a variety of cell processes
including the control of cell growth, proliferation, differentiation and
apoptosis [5]. TGF-β1 signals through serine-threonine kinase type I
and II transmembrane receptors, initiating receptor I phopsphoryla-
tion and signal transduction via activation of canonical (SMAD) and
non-canonical (p38MAPK, ERK, JNK, PI3K/Akt) pathways [6,7]. TGF-
Fig. 1. Establishment of ﬁbrotic phenotype in human proximal tubular epithelial cells.
(A) Western blot of markers of ﬁbrosis (E-cadherin, N-cadherin) and TGF-β1 signaling
(CTGF, Jagged1) in HK-2 cells stimulated with TGF-β1 (5 ng/ml) for 48 h versus unsti-
mulated controls (n=3). (B) Real-time quantitative PCR validation of differentially
expressed transcripts from RNA-Seq experiment. Quantitative TaqMan PCR was per-
formed in unstimulated HK-2 cells (gray bar) and HK-2s stimulated with TGF-β1
(black bars). Expression was normalized to 18S. Data are plotted as mean±SE.
*Pb0.05, Student's unpaired t test, n=3 per group.
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cells which de-differentiate into a moremesenchymal-like phenotype
in response to the cytokine. Such responses are characterized by a
switch in predominant cadherins from E-cadherin (epithelial) to N-
cadherin (mesenchymal), and increased vimentin, α-smooth muscle
actin, CTGF and the Notch ligand Jagged [8].
The current study sought to gain greater insight in relation to dys-
regulated TGF-β1 activation in DN using RNA-Seq. Thus differential
transcriptional responses to TGF-β1 stimulation of human renal epi-
thelial (HK-2) cells was investigated by RNA-Seq; with comparative
sensitivity analysis to DNA microarrays. The accuracy and sensitivity
of DNA microarrays can be limited by probe coverage restrictions
and relative insensitivity to low abundance transcripts [9].
Sequence-based approaches overcome many of these limitations,
and here we demonstrate that RNA-Seq identiﬁes a considerably larg-
er number of TGF-β1-regulated genes.
Using these in vitro datasets, we compared TGF-β1-regulated genes
identiﬁed by RNA-Seq with available expression data from micro-
dissected human kidney biopsies, at various stages of DN versus healthy
controls [10], and deﬁned a common subset of 179 TGF-β1-related
genes, comprising both established and potentially novel regulators of
renal ﬁbrosis. By silencing the expression of several of these genes, we
have demonstrated their functional signiﬁcance to the TGF-β1 ﬁbrotic
signal in renal epithelial cells. Finally, we tested whether the large set
of TGF-β1-regulated low-abundance transcripts identiﬁed in the cell
model sequence dataset could inform the selection of novel transcripts
for detection in human DN biopsy samples. Using this strategy, we
have identiﬁed several genes not previously available on our human
DN microarray platforms, and successfully validated these responses
in human DN biopsy samples versus living donors.
2. Materials and methods
2.1. Cell culture
Human kidney epithelial cells (HK-2) were purchased from the
European Tissue Culture Collection (ETCC). HK-2 cells were cultured
at 37 °C in a humidiﬁed atmosphere of 95% air/5% CO2, and main-
tained in DMEM-F12 (Sigma) supplemented with 2 mM L-glutamine,
100 U/ml penicillin, 100 μg/ml streptomycin, 10 ng/ml EGF, 36 ng/ml
hydrocortisone, 3 pg/ml triiodothyronine and 5 μg/ml insulin–5 μg/
ml transferrin–5 ng/ml selenium (ITS) solution (Sigma-Aldrich).
Cells were subcultured using trypsin–EDTA at a ratio of 1:5. HK-2
cells were plated in triplicate for stimulation with TGF-β1 (5 ng/ml
PromoCell) or vehicle for 48 h. Three independent experiments
were performed. Triplicate samples for each time point being pooled
on each occasion, giving a total of 6 samples for RNA-Seq analysis.
Total RNA extraction was performed using an RNeasy RNA extraction
kit according to the manufacturer's protocol (Qiagen). RNA quality
was assessed using a Bioanalyzer 2100 (Agilent).
2.2. Western blot and qRT-PCR
Lysates were harvested in RIPA lysis buffer containing 50 mM
Tris–HCl, pH 7.4, 1% Nonidet P-40, 0.25% sodium deoxycholate,
150 mM NaCl, and 1 mM EDTA, supplemented with 1 mM phenyl-
methylsulfonyl ﬂuoride, 1 mM sodium orthovanadate, 1 mM sodium
ﬂuoride and a protease inhibitor cocktail (pepstatin 1.0 μg/ml, leu-
peptin 1.0 μg/ml, bestatin 1.0 μg/ml, and aprotinin 1.0 μg/ml)
(Sigma-Aldrich). Cell lysates were centrifuged at 20,000 g for 15 min
at 4 °C and total protein was estimated using the Bradford assay
(BioRad). For Western blot analysis, normalized protein extract was
resolved by SDS-PAGE. Proteins were then transferred onto Immobi-
lin P-transfer membranes (Millipore), blocked with TBS-T (25 mM
Tris–HCl, pH 7.6, 150 mMNaCl, and 1.0% (v/v) Tween 20) supplemen-
ted with 5% (w/v) non-fat dried milk and then incubated with thefollowing antibodies: β-actin (1:20,000; Sigma-Aldrich), CTGF
(1:2000; Santa-Cruz), E-cadherin, (1:1000; BD Biosciences), N-
cadherin, (1:1000; BD Biosciences) and Jagged1 (1:2000; Santa-
Cruz). Membranes were subsequently incubated with horseradish
peroxidase-linked secondary antibodies (New England Biolabs).
Blots were developed using enhanced chemiluminescence reagents
(Supersignal™). cDNA was synthesized from 1 μg of total RNA using
the Superscript-II RNase H-Reverse transcriptase cDNA synthesis kit
(Invitrogen). Real-Time TaqMan PCR was used to quantify relative
gene expression levels of CDH1, CDH2, CTGF, JAG1, SERPINE1,
IGFBP3, CGB, SOD2, PLAT and BIRC3 from total RNA extracted from
HK-2 cells. The PCR primers and TaqMan probe for all assays were
supplied as a pre-optimized single tube primer/probe Gene Expres-
sion Assay (Applied Biosystems). 18S rRNA was used as an endoge-
nous control for normalization of the target genes. PCR reactions
were set up with Taqman Universal PCR Master Mix in a 10 μl reac-
tion using 1:20 diluted cDNA. Ampliﬁcation was performed on the
7900HT Sequence Detection System (Applied Biosystems). Results
were analyzed using the ΔCt method of analysis.
2.3. Library preparation for Illumina sequencing
The Illumina library was prepared according to the manufacturer's
instructions. Brieﬂy, we used Dynal oligo (dT) beads (Invitrogen) to
isolate poly (A) mRNA from 6 μg of total RNA. Zinc-mediated frag-
mentation of mRNA was performed using an RNA fragmentation kit
(Ambion), followed by ﬁrst- and second-strand cDNA synthesis
using random hexamer primers. Following cDNA synthesis, an ‘end-
repair’ reaction was performed using a combination of T4 DNA poly-
merase and E. coli DNA polymerase I Klenow Fragment. A single ‘A’
base was added to the 3′ end of end-repaired fragments by using
3′-to-5′ exo-nuclease, followed by ligation of the Illumina adapter
using T4 DNA ligase. Adapter ligated DNA templates at approximately
Table 1
Top 20 signiﬁcantly upregulated/downregulated genes in HK-2 cells stimulated with
TGF-β1.
Gene Reads* Log2 fold change Adjusted P-value
TGFBI 10928.30 2.67 3.40E-199
IGFBP3 1290.22 2.59 3.23E-198
COL1A1 1344.63 2.42 3.45E-174
SLCO2A1 752.95 2.21 2.97E-107
SERPINE1 13607.37 2.44 3.14E-101
IL11 538.53 2.32 9.30E-96
CGB8 71.08 4.98 1.72E-76
C20orf58 333.50 1.80 1.37E-57
TMEPAI 2268.56 1.95 2.61E-54
C4orf26 216.30 2.27 3.81E-54
JAG1 784.27 2.12 3.22E-50
ADAM12 534.83 1.71 5.37E-47
TAGLN 3525.86 1.75 1.35E-46
GDF6 100.20 2.92 1.97E-46
CDH2 1812.90 1.54 1.27E-44
CGB5 31.53 4.66 5.27E-40
KRT7 956.47 1.51 1.69E-39
CCDC80 5626.09 1.65 4.31E-39
ANKRD1 1359.09 1.54 3.27E-38
ID1 209.54 2.02 1.73E-34
SEMA5B 17.32 −4.91 4.10E-16
PTGDS 627.43 −2.80 7.90E-200
C3 2927.84 −2.07 1.92E-154
SERPINA1 1161.42 −2.12 1.88E-93
ITGB8 547.49 −2.28 6.77E-92
FXYD2 961.53 −2.15 1.30E-67
TNFSF10 961.02 −1.86 5.92E-66
CX3CL1 723.63 −1.65 1.07E-62
LTB 327.02 −2.56 3.27E-62
SOD2 1591.96 −1.79 2.37E-57
CYP1B1 491.70 −1.90 1.64E-54
FOS 221.60 −2.44 4.42E-53
TPCN1 866.23 −1.43 4.65E-45
PRODH 419.99 −1.61 1.25E-44
NPR1 927.00 −1.68 2.18E-44
SLCO4A1 258.34 −1.95 2.36E-42
C20orf75 1990.00 −1.25 1.39E-40
EDN2 207.77 −1.90 4.81E-40
PLAU 4235.28 −1.29 6.00E-38
CXCL2 290.97 −1.76 5.11E-36
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and ampliﬁed by PCR. Library quality was assessed on a 2% agarose
gel and quantitation was performed using a Qubit™ Flurometer and
HS dsDNA kit (Invitrogen).
2.4. Read mapping and statistical analysis
RNA-Seq reads were mapped to the human genome (UCSC version
hg18) using the Bowtie software [11]. Gene counts were generatedTable 2
Top 15 signiﬁcantly changed KEGG pathways in response to TGF-β1.
Term Pathway Size Ex
Focal adhesion 201 23
Cell adhesion molecules (CAMs) 133 15
ECM-receptor interaction 84 9.
Complement and coagulation cascades 69 7.
Pathways in cancer 327 37
Axon guidance 129 14
Regulation of actin cytoskeleton 215 24
Small cell lung cancer 84 9.
Leukocyte transendothelial migration 118 13
TGF-beta signaling pathway 87 10
Endocytosis 185 21
p53 signaling pathway 68 7.
Chronic myeloid leukemia 75 8.
Hypertrophic cardiomyopathy (HCM) 85 9.
Propanoate metabolism 33 3.from mapped reads using the ERANGE library of python scripts,
which incorporates methods for mapping spliced reads and predict-
ing most likely mapping location for reads mapped in multiple loca-
tions. Final gene counts were imported into R; differentially
expressed genes were identiﬁed using the DESeq library of functions.
For differential expression analysis, RNA-Seq data was ﬁltered to in-
clude only genes with at least three reads mapped in at least two
lanes, to avoid biologically ambiguous results. P-values were adjusted
for multiple testing, using the method proposed by Benjamini and
Hochberg [12].
2.5. Promoter analysis
Expression data were ﬁrst scaled and centered to zero to avoid
spurious correlations between strongly differentially expressed
genes. Genes were then subdivided into groups using MBC, as imple-
mented using the Mclust library of functions in R. Only genes which
were assigned to a single cluster with greater than 90% probability
were retained for further analysis. Analysis of promoter sequences
in these 584 genes was performed using Genomatix Gene2promoter
to extract the 1 kb promoters for each group of genes (www.
genomatix.de/en/index.html). Each group was tested with Genoma-
tix RegionMiner for overrepresentation of TFBS against a promoter
background. Group over- and underrepresentation of speciﬁc TFBS
families were hierarchically clustered using Gene Cluster 3.0
(bonsai.hgc.jp/~mdehoon/software/cluster/). Group functional
annotations were attributed using the DAVID Bioinformatics
Database.
2.6. Statistical analysis of microarray datasets
Detailed methods on the experimental design for the HK-2microar-
ray are previously published [13]. Published human DN microarray
data [10] was downloaded from Nephromine (www.nephromine.
org). Array data were ﬁrst normalized using the gcrma library [14] in
R (www.cran.org), then ﬁltered to remove genes with mas5 ‘absent’
calls on all arrays, using the detection.p.val function in the simpleaffy li-
brary [15] in R. The limma library [16] was used to identify differential-
ly expressed genes; p values were adjusted for multiple testing, using
themethod proposed by Benjamini and Hochberg [12]. Cluster analysis
of log transformed normalized expression data was performed using
Hierarchical Clustering Explorer (www.cs.umd.edu/hcil/hce/).
2.7. siRNA transfections of renal epithelial cells
siGENOME SMARTpool ARK5/TGFBI siRNA, and siGENOME RISC-
Free control siRNA were purchased from Dharmacon. siRNAs were
transfected into HK-2 cells at 60% conﬂuence using Lipofectaminepected gene count Observed gene count P-value
.22 50 5.89E-08
.37 36 5.09E-07
70 26 1.30E-06
97 22 4.97E-06
.78 64 9.17E-06
.90 31 4.31E-05
.84 41 6.90E-04
70 20 1.10E-03
.63 25 1.71E-03
.05 20 1.74E-03
.37 34 3.65E-03
86 16 3.82E-03
66 17 4.39E-03
82 18 7.29E-03
81 9 1.03E-02
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were then stimulated with TGF-β1 (5 ng/ml PromoCell) or vehicle
for 48 h.
2.8. qRT-PCR validations in human biopsy samples
Human renal biopsy specimens were procured in an international
multicenter study, the European Renal cDNA Bank-Kroener-Fresenius
Biopsy bank (ERCB-KFB). Biopsies were obtained from patients after in-
formed consent and with approval of the local ethics committees. Fol-
lowing renal biopsy, the tissue was transferred to RNase inhibitor and
microdissected into glomerular and tubular fragments. Total RNA was
isolated frommicro-dissected tubulointerstitum as described previous-
ly [17]. Reverse transcription and real-time RT-PCR were performed as
reported earlier [17]. Pre-developed TaqMan reagents were used for
human ANKRD56 (Hs02576315_s1), ENTPD8 (Hs01651150_m1), as
well as the reference gene 18S rRNA (Applied Biosystems). The expres-
sion of ANKRD56 and ENTPD8 was normalized to 18S rRNA. The mRNA
expression was analyzed by standard curve quantiﬁcation [18]. For the
real time RT-PCR data statistical analysis was performed using Kruskal–
Wallis and Mann–Whitney U test.
3. Results
3.1. Global expression proﬁle of HK-2 cells treated with TGF-β1
Immortalized human proximal tubular epithelial (HK-2) cells were
used to examine ﬁbrotic responses to TGF-β1 (5 ng/ml; 48 h). TGF-β1
induced a loss of E-cadherin (epithelial marker) and gain of N-
cadherin (mesenchymal marker), as observed byWestern blot analysis
(Fig. 1A). Increased expression of connective tissue growth factor
(CTGF) and the Notch pathway ligand Jagged1 was also observedFig. 2. Transcriptional changes in TGF-β1 signaling pathway. RNA-Seq data are mapped to
sponse to TGF-β1 treatment is illustrated in node border colors ranging from blue (downre
membrane. Nodes marked ‘DNA’ represent transcriptional regulatory interactions.following TGF-β1 treatment (Fig. 1A). We have previously shown that
Jagged1 expression is elevated in HK-2 cells treated with TGF-β1, and
also in biopsies from DN patients, with co-localization in areas of TIF
[13]. Changes in the RNA levels of E-cadherin, N-cadherin, Jagged1
and CTGF reﬂected altered protein expression in these cells (Fig. 1B).
Having validated TGF-β1-induced signaling in HK-2 cells, we then
examined global gene expression changes using massively parallel
sequencing technology (RNA-Seq). 2027 genes were signiﬁcantly reg-
ulated by TGF-β1 treatment (828 upregulated and 1199 downregu-
lated; Supplementary Table 1 online). Top 20 upregulated and
downregulated genes ranked according to p-value are described in
Table 1. The top signiﬁcantly upregulated gene (TGFBI) encodes
transforming growth factor, beta-induced protein, an RGD-
containing protein that binds to type I, II and IV collagens. Among
the top downregulated genes were semaphorin 5B (SEMA5B) and
prostaglandin D-synthase (PTGDS). The downregulation of PTGDS is
noteworthy given the proposed role of its product prostaglandin D2
in inhibiting TGF-β1-induced EMT in experimental system [19], and
evidence of nephropathy (glomerular hypertrophy, tubular damage
and ﬁbrosis) in PTGDS knockout mice [20].
Signaling pathways regulated by TGF-β1 included: focal adhesion,
cell adhesion, ECM-receptor interaction, and complement and coagu-
lation pathways (Table 2). A total of 21 genes within the TGF-β1 sig-
naling network were differentially expressed, including the induction
of TGFB2, TGFB3, TGF-β receptor 1 (TGFBR1) and several downstream
regulators: Smad ubiquitination regulatory factor 2 (SMURF2),
SMADs 4, 7 and 9 (Fig. 2). Enriched gene ontology (GO) cellular com-
partment categories included genes involved in cytoskeletal reorgani-
zation and adhesion, such as basement membrane, extracellular
space, integrin complex, focal adhesion and cell-cell adherens junc-
tion (Supplementary Table 2 online). Within the RNA-Seq dataset,
134 differentially expressed transcriptional regulators were identiﬁedthe pathway; green nodes show differentially expressed genes. Log-fold change in re-
gulated) to yellow (upregulated). Double and dashed lines represent cell and nuclear
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lated TFs implicated in ﬁbrotic disorders and EMT: ZEB1, TCF4,
SMAD3, SMAD7, ID1, ID3 (Supplementary Table 3 online).3.2. Promoter analysis —transcriptional network activation
We inferred putative TGF-β1-driven transcription regulation
changes by identifying signiﬁcantly overrepresented TFBSs among
the set of differentially regulated genes using model based clustering
(MBC) methods [21]. Using MBC we partitioned differentially
expressed genes into 36 independent non-redundant groups and
proximal promoter sequence of 1kbp upstream of each gene was re-
trieved and each group tested for over- and underrepresentation of
TFBSs against a promoter background. Hierarchical clustering based
on TFBSs distribution revealed that clustering occurred not according
to up or down regulation of expression but more closely by functional
annotation (Fig. 3). Clusters split primarily into two segments: the
larger cluster (cluster 1) which annotated signiﬁcantly with path-
ways relating to focal adhesions, ECM receptor interaction, cell adhe-
sion molecules and other ﬁbrosis related pathways (Supplementary
Table 4 online). Within the second, smaller cluster (cluster 2)
enriched pathways included MAPK signaling and colorectal cancer,
with an absence of functional annotation with ﬁbrosis related path-
ways observed. Two sets of overrepresented TFBS, containing 8 andFig. 3. Analysis of overrepresented TFBS among clusters of signiﬁcantly regulated genes. Dif
promoter regions were assessed for overrepresented (red) and underrepresented (green) T13 TFBS respectively segregated with cluster 1, constituting a cohort
of TFs putatively driving the ﬁbrotic signal within our experiment
(Fig. 3) (Supplementary Table 5 online). Among these, an enrichment
of binding sites for NFκB, DEAF1 (deformed epidermal autoregulatory
factor 1) and E2F7 (E2F transcription factor 7) was evident.3.3. Comparison of RNA-Seq and microarray data — RNA-Seq identiﬁes a
cohort of low abundance transcripts
We previously performed microarray analysis of HK-2 cells trea-
ted with TGF-β1 using an identical design to the present study
(GEO: GSE23338). Comparison of mean expression levels of all
genes in the RNA-Seq dataset to those determined by Affymetrix mi-
croarray (11,033 genes) showed a highly signiﬁcant signal correla-
tion; Pearson correlation of 0.69, pb2.2e−16 (Fig. 4A). In a
comparison of log fold-change value for each gene, we divided
genes into three tertiles of expression level based on the RPKM values
(average number of sequence reads per kilo-base pair of coding se-
quence, per million reads mapped) [22] and found increasing expres-
sion correlation for genes with higher expression level (Fig. 4B). In
order to determine the extent of additional information available
from RNA-Seq data, we compared the differentially expressed genes
in both datasets (microarray — 199; RNA-Seq — 2027) (Fig. 4C).
Among the 352 low expression genes detected only by RNA-Seq areferentially expressed genes in RNA-Seq were separated into 36 clusters (G1-36). 1Kbp
FBS in each group.
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alpha 1, integrin alpha M and pleckstrin (Supplementary Table 6 on-
line). Similarly, in comparing RNA-Seq and microarray on the basis of
the genes present in the array data set (8632 genes) we observed
greater overlap at higher expression level — and consistently higher
sensitivity in detection of differentially expressed genes on the
RNA-Seq platform (1517 genes with RNA-Seq; 199 with microarray).
We then compared signiﬁcantly enriched pathways (pb0.05) that
were detected on each platform (Fig. 4D). RNA-Seq detected four
times more signiﬁcantly regulated pathways, and among the path-
ways detected by RNA-Seq only were those known to play an impor-
tant role in renal ﬁbrosis, such as focal adhesion, cell adhesion
molecules and ECM receptor interaction.
In order to validate ﬁndings from the sequence data, six genes
were selected for qRT-PCR analysis based on their respective RNA-
Seq RPKM expression values (high, medium, low expressors). Three
upregulated genes — SERPINE1 (high), IGFBP3 (medium), CGB5
(low); and three downregulated genes — SOD2 (high), PLAT (medi-
um), and BIRC3 (low) were assessed. All genes were successfully
validated, with TGF-β1 treatment inducing SERPINE1, IGFBP3 and
CGB, and repressing SOD2, PLAT and BIRC3 expression (Fig. 4E). Com-
parison of qRT-PCR fold-changes with RNA-Seq and microarray data
indicated that for the six selected targets, RNA-Seq data best correlat-
ed with real-time validations.Fig. 4. Comparison of RNA-Seq to microarray of TGF-β1 effects on gene expression in HK-2
compared to expression level on the microarray (calculated from hybridization intensity). (B
as high (yellow), medium (blue), or low (black) expressors, based on RNA-Seq RPKM for ea
croarray, subdivided by expression level (RNA-Seq RPKM value; microarray hybridization in
and microarray (blue). (E) Log-fold changes of six selected genes in RNA-Seq (purple bar),
HK-2s stimulated with TGF-β1 (5 ng/ml; 48 h). Expression was normalized to 18S. Data are3.4. Intersection of in vitro data with human DN expression data
In order to extrapolate sequence data from the HK-2 cell model
to human DN, we compared our in vitro sequence data to available
human tubulo-interstitial array data of DN patients (n=11) com-
pared to minimal change disease patients (MCD; n=4) and controls
(living donors; n=3) [10]. Of the 2027 genes identiﬁed by RNA-Seq
as signiﬁcantly regulated by TGF-β1, corresponding microarray ex-
pression data was available for 1356 genes (Fig. 5A). A total of
179 genes were signiﬁcantly differentially expressed in both the
RNA-Seq and human DN datasets (Fig. 5B) (Supplementary Table 7
online). Gene ontology analysis of the 179 genes indicated an en-
richment of ECM and cytoskeleton-associated gene products (Sup-
plementary Table 8 online). Upregulated genes included: collagen
family members (COL4A1, COL4A2, COL16A1); key markers of EMT
and TIF (VIM, THBS1, ITGAV); and the Notch pathway ligand
JAGGED1.
Closer examination of known early phase EMT TFs and adhesion
molecules revealed expression variation in SNAI2, CLDN4 and
CLDN3 that was only evident in mild DN relative to healthy donor
(Supplementary Fig. 1 online). The SNAIL family of TFs are induced
in response to TGF-β1, in a SMAD-dependent manner, and act to re-
press epithelial marker gene expression (including claudins), and ac-
tivate mesenchymal markers [23]. Expression of SNAI2 appeared tocell line. (A) Raw signal comparison. In left panel, mean RNA-Seq RPKM of each gene is
) Comparison of log FC of each gene from RNA-Seq to microarray. Genes were classiﬁed
ch gene. (C) Degree of overlap of differentially expressed genes from RNA-Seq and mi-
tensity). (D) Overlap of signiﬁcantly regulated KEGG pathways from RNA-Seq (yellow)
microarray (blue bar) and corresponding quantitativeTaqMan PCR validation (grey) in
plotted as mean±SE. *Pb0.05, Student's unpaired t test, n=3 per group.
Fig. 5. RNA-Seq identiﬁes a TGF-β1 regulated gene set with overlapping expression proﬁle in human DN. (A) 2027 genes were identiﬁed as signiﬁcantly differentially expressed in
renal epithelial cells in response to TGF-β1 treatment. Heatmap of gene expression patterns of 1356/2027 genes available from microarray data of renal biopsies from human di-
abetic nephropathy (DN; n=11) versus living donor (LD; n=3) and minimal change disease (MCD; n=4) controls. (B) A subset of 179 genes was signiﬁcantly differentially
expressed in both RNA-Seq and human DN microarray datasets. Heatmap of log-fold changes of 179 genes in HK-2 cells stimulated with TGF-β1 (5 ng/ml; 48 h), and gene expres-
sion patterns of corresponding 179 genes from microarray data of renal biopsies from human diabetic nephropathy (DN; n=11) versus living donor (LD; n=3) and minimal
change disease (MCD; n=4) controls. Microarray data are log2 median-centred intensities. Green — downregulated gene expression; Red — upregulated gene expression.
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moderate and severe DN; the opposite pattern was noted in CLDN3
and CLDN4. These changes were moderately signiﬁcant at nominal
p=0.037, 0.016 and 0.027 for SNAI2, CLDN3 and CLDN4, respectively.
Similar patterns of change were observed in sequence data in re-
sponse to TGF-β1 for SNAI2 and CLDN3 (nominal p=2.83e−05 and
2.45e−05). Additional cell adhesion-related genes showing signiﬁcant
transient downregulation in mild DN included LAMC2, RHOB, CDH19
and SELE (data not shown).3.5. TGFBI and ARK5: functional role in TGF-β1-driven ﬁbrotic signaling
in renal epithelial cells
Among the genes upregulated by TGF-β1 and also elevated in
human DN was ARK5, encoding a serine/threonine AMPK-related ki-
nase previously reported to be a key player in tumor invasion and
directly activated by Akt [24]. To demonstrate the biological signiﬁ-
cance of the RNA-Seq data, the effect of siRNA-mediated inhibition
of these genes on EMT and TGF-β1 signaling was assessed. Inhibi-
tion of ARK5 signiﬁcantly attenuated TGF-β1-induced Jagged1 and
N-cadherin RNA expression towards basal expression levels, with
no effect seen on E-cadherin or CTGF expression. These data were
subsequently validated at the protein level (Fig. 6A and B). TGFBI
was the most signiﬁcantly upregulated gene in response to TGF-β1
and is also elevated in human DN. Silencing of TGFBI resulted in
an induction of basal E-cadherin expression, evident at both the
RNA and protein level (Fig. 7A and B), suggesting that TGFBI nega-
tively regulates E-cadherin expression in renal epithelial cells. The
observed induction of E-cadherin expression was reversed in the
presence of TGF-β1, suggesting that while TGFBI may negatively
regulate E-cadherin expression, it is not essential for TGF-β1-
induced loss of E-cadherin.3.6. ANKRD56 and ENTPD8 are low abundance transcripts down-
regulated in renal epithelial cells by TGF-β1 and also in human DN renal
biopsies
In order to determine whether RNA-Seq data from our cell model
could inform the selection of novel low expression genes in human
DN, previously undetectable by microarray, we selected a cohort of
low abundance transcripts from the RNA-Seq dataset and validated
these by qRT-PCR in human DN samples (n=14) versus living
donor controls (n=7). Expression changes in ﬁve genes were mea-
sured — ANXA8, ANKRD56, ENTPD8, TSHZ3 and NTF6A. For three
genes (ANXA8, TSHZ3, NTF6A), the low overall expression levels
were below the threshold of detection by qRT-PCR. ANKRD56 and
ENTPD8 expression levels were signiﬁcantly lower in DN biopsies,
mimicking the expression response observed in TGF-β1 stimulated
HK-2 cells (Fig. 8).
4. Discussion
TGF-β1 is implicated in multiple ﬁbrotic disorders, and is recog-
nized as a major driver of renal ﬁbrosis including renal tubule injury.
TGF-β1 stimulation of cultured renal epithelia is a conventional
model of DN associated TIF [25–28]. However the full extent of tran-
scriptomic response to TGF-β1 treatment has not been clariﬁed. Using
RNA-Seq we have performed detailed analyses of transcriptional
changes induced by pro-ﬁbrotic TGF-β1 in renal tubule epithelial
cells. By comparing RNA-Seq and microarray data using identical ex-
perimental conditions, we demonstrate that while there is a high de-
gree of correlation between both platforms, RNA-Seq uniquely
identiﬁes a large cohort of differentially expressed low abundance tran-
scripts. By comparing our in vitromodel RNA-Seq data with array data
from human DN renal biopsies we have: deﬁned a subset of 179 co-
regulated genes, which may represent the TGF-β1-driven signature in
Fig. 6. Role for ARK5 in TGF-β1-induced ﬁbrosis in renal epithelial cells. (A) TaqMan quantitative PCR analysis of Jagged1, N-cadherin (CDH2), E-cadherin (CDH1) and CTGF in HK-2
cells transfected with ARK5 siRNA in the absence (gray bar)/presence (black bar) of TGF-β1 (5 ng/ml; 48 h). (B) Representative Western blot of Jagged1, N-cadherin (CDH2), E-
cadherin (CDH1) and CTGF HK-2 cells transfected with ARK5 siRNA, respectively. HK-2 cells transfected with scrambled siRNA were selected as a control. For TaqMan PCR, expres-
sion was normalized to GAPDH. Data are plotted as mean±SE. *Pb0.05, Student's unpaired t test, n=3 per group.
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β1 signaling in renal epithelial cells; and identiﬁed the low abundance
transcripts ENTPD8 and ANKRD56 as differentially expressed in human
DN renal biopsies. These data provide a comprehensive overview of
transcriptomic responses of renal epithelia exposed to TGF-β1 and de-
ﬁne those genes most relevant in the context of DN.
By examining the promoter regions of TGF-β1 responsive genes
we have deﬁned a series of potential transcriptional regulators.
Among these, an enrichment of binding sites for NFκB was evident.
Several studies have previously reported the activation of the NFκB
signaling pathway in progressive DN [10,29]. This would suggest
that the global transcriptional response in the in vitro dataset
mimics the response seen in human DN. Though increased tran-
scription factor expression is not a functional necessity for increasedtranscription factor activity (i.e. increased target expression), a
number of these TFs such as KLFs, GLI1, EGR1 and NFκB2 were also
found themselves to be differentially regulated in the RNA-Seq
dataset.
We have shown that, as expected, sequencing technology offers
substantially enhanced sensitivity in detecting differentially expressed
genes when compared with microarrays. Several studies have
reported the advantages of sequencing technology versus array data
[30,31]. In our model system, RNA-Seq detected approximately 10
times more differentially expressed genes than array technology,
and as a consequence three times more differentially regulated path-
ways. The lesser degree of correlation in low expression genes is
likely explained by non-speciﬁc background hybridization on the
array [32].
Fig. 7. Silencing of TGFBI induces E-cadherin expression in renal epithelial cells. (A)
TaqMan quantitative PCR analysis of E-cadherin (CDH1) expression in HK-2 cells trans-
fected with TGFBI siRNA in the absence (gray bar)/presence (black bar) of TGF-β1
(5 ng/ml; 48 h). (B) Representative Western blot of E-cadherin (CDH1) expression in
HK-2 cells transfected with TGFBI siRNA. HK-2 cells transfected with scrambled
siRNA were selected as a control. For TaqMan PCR, expression was normalized to
GAPDH. Data are plotted as mean±SE. *Pb0.05, Student's unpaired t test, n=3 per
group.
Fig. 8. ANKRD56 and ENTPD8 are differentially expressed in human DN. (A) TaqMan
quantitative PCR analysis of ANKRD56 and ENTPD8 in human DN renal biopsy samples
(DN n=13; black) versus living donor controls (LD: n=7; gray). Data are plotted as
mean±SE. The graphs for ANKDR56 and ENTPD8 show expression ratios of each
gene normalized to 18S rRNA. Statistical analysis was performed using Kruskal–Wallis
and Mann–Whitney U test (mean±SE. *Pb0.05) (B) RNA-Seq data fold-change for
ANKRD56 and ENTPD8 in HK-2 cells stimulated with (black)/without (grey) TGF-β1.
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context of human DN, we compared sequence data to expression data
from human kidney biopsies enriched for tubulointerstitium from pa-
tients at varying stages of DN. In this analysis we found a signature of
179 genes commonly regulated in the human and in vitromodels. We
investigated the functional signiﬁcance of two of these commonly
upregulated genes: ARK5 and TGFBI. Suppression of ARK5 expression
in tubular epithelial cells attenuated TGF-β1 signaling. ARK5 encodes
an AMPK-related serine/threonine kinase implicated in metastasis
and acts downstream of Akt [24,33]. We have previously detected in-
creased levels of TGF-β1 signaling and PKB/Akt activity in the kidney
tubules of a Goto-Kakizaki rat model of type 2 diabetes, suggesting
that this signaling cascade may be involved in DN-associated EMT in
vivo [34]. By silencing ARK5 expression, TGF-β1-driven gain of N-
cadherin was impeded. A putative role for ARK5 in mediating TGF-
β1-driven Notch pathway expression is also evident, with ARK5 inhi-
bition preventing the induction of Notch ligand—Jagged1. Expression
of the Notch pathway ligand Jagged1 was elevated in human DN, and
we have recently shown that several genes involved in the Notch
pathway are differentially expressed in renal biopsies from individ-
uals with DN [13]. TGFBI encodes an ECM protein induced by TGF-
β1 that is associated with other ECM proteins and functions as a
ligand for integrins [35]. Inhibition of TGFBI has been shown to signif-
icantly reduce metastasis in colon cancer [36]. Here we demonstrate
that basal expression of E-cadherin was signiﬁcantly upregulated
upon TGFBI silencing, suggesting this protein may act as a negative
regulator of E-cadherin expression. The fact that TGF-β1 still sup-
pressed E-cadherin levels in TGFBI silenced cells would indicate that
TGFBI is not an absolute requirement.
Examination of expression changes of an early phase regulator of
EMT, the transcriptional repressor SNAI2, and SNAI2 targets (CLDN3,
CLDN4) [23,37], revealed that SNAI2 was upregulated in mild DN pa-
tients versus healthy donor, and subsequently restored to basal levels
in moderate and severe DN patient. A corresponding repression in
CLDN3 and CLDN4 expression was observed in mild DN patients,
which was subsequently restored in moderate and severe DN pa-
tients. Comparison of these data with our in vitromodel data revealed
that the expression changes observed in mild DN best matched the
observed response to TGF-β1 in renal epithelial cells.
The higher degree of sensitivity offered by RNA-Seq allows for
the identiﬁcation of low abundance transcripts that are undetectable
by microarray [38,39]. Using the additional information we acquired
from sequence data on low abundance transcripts regulated by TGF-
β1, which were previously not available for measure on our micro-
array panels, we selected several of these and measured mRNA
levels in renal biopsy material from DN patients versus living
donor controls. Of the ﬁve transcripts measured, two of these
were detected (ENTPD8 and ANKRD56) and validated the TGF-β1
response in renal epithelial cell sequence data. In human DN we ob-
served a downregulation of ENTPD8 expression, which encodes an
intracellular enzyme that regulates the availability of extracellular
nucleotide levels (ATP, ADP) to receptors [40]. Aberrant nucleotide
signaling has previously been shown to promote injury in DN,
with another family member, ENTPD1, shown to be a protective fac-
tor in DN [41]. ANKRD56 was also downregulated in human DN in
the present study, and EST database analysis of both human and
mouse genomes shows that ANKRD56 RNA is present in kidney, in-
testine, mammary gland, muscle and uterus http://www.ncbi.nlm.
nih.gov/UniGene/clust.cgi?ORG=Hs&CID=257292. ANKRD56 con-
tains multiple ankyrin repeats consisting of 30–34 amino acid resi-
dues, which mediate protein–protein interactions[42]. Recently,
inactivation of ANKRD26 was shown to induce obesity and diabetes
in mice, hinting at a putative role for these proteins in disease
[43,44]. Currently the precise roles of ENTPD8 and ANKRD56 remain
undeﬁned and the function of these genes in the context of DN
needs to be addressed.
598 E.P. Brennan et al. / Biochimica et Biophysica Acta 1822 (2012) 589–599We recognize several limitations to the present study which need
to be considered when interpreting these results. While we have
compared our in vitro model RNA-Seq dataset with a human disease
microarray dataset, a comparison on identical platforms (i.e. RNA-
Seq on human DN biopsies) would be a more powerful approach to
identify low abundance transcripts. However, presently no such suit-
able dataset is available. Furthermore, the human disease dataset
employed in this study is limited with respect to sample size and clin-
ical parameter information necessary to assess a correlation between
differentially expressed transcripts and markers of disease progres-
sion. Finally, comparison of the cell model dataset with in vivo expres-
sion datasets is an attractive approach which we intend to develop in
future studies. It is noteworthy that as yet no RNA-seq datasets are
available from in vivo models of DN, notwithstanding the controver-
sies about such models [45].
In summary, using tubular epithelial cells stimulated with the pro-
ﬁbrotic cytokine TGF-β1 as a model of renal ﬁbrosis, we have per-
formed a comprehensive analysis of the transcriptome response
using both sequence and array platforms. In this study we: (1) iden-
tiﬁed a cluster of ﬁbrosis-related genes predicted to be regulated by
a relatively small group of TFs, including both established and novel
regulators of EMT. These TFs may act as master regulators of ﬁbrosis
in this cell model and are worthy of follow up functional studies;
(2) we have jointly analyzed our in vitro data with human DN biopsy
data in order to deﬁne a co-regulated subset of genes. These genes de-
ﬁne the responsive subset in human DN to TGF-β1, a key driver of
renal ﬁbrosis; and ﬁnally (3) using RNA-Seq data from our renal epi-
thelial cell model system, we have identiﬁed novel low abundance
transcripts downregulated in human DN, providing evidence that
not all DN-associated transcripts have been identiﬁed. Targeted inter-
vention of these genes may offer novel therapeutic approaches in an
effort to attenuate the initiation and progression of renal ﬁbrosis.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.bbadis.2012.01.008.
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